DiLenge predicts biopharma companies will ‘take a hit’ in infrastructure bill

As he prepares to leave BIO after 15 years, Tom DiLenge previewed the urgent policy challenges the industry will face in the coming months, including pending drug price control legislation that could reshape the U.S. market.

DiLenge, who has been BIO’s president for advocacy, law & public policy for the past five years after serving as general counsel for a decade, said he plans to “continue to contribute to the biotech ecosystem” by working in-house at an investment firm, biopharmaceutical company or related enterprise. ...